Memorial Sloan Kettering opens up its cancer data through OpenEvidence. Which healthcare and biotech entrepreneurs made the Forbes 400 for the first time. Persistent generic cancer drug shortages. These stories and more in this week’s Forbes Innovation…
He once mused about how he could become a billionaire. Now he’s worth more than $25 billion.
Market euphoria has vaulted Shanghai Enflame’s cofounders into the world’s billionaire ranks, raising questions about how long the rally can last.
A little-known company called Fluidstack has become a test bed for Google’s plans to push its own AI chip. That’s helped it hit a $18 billion valuation and minted its founders as new billionaires.
Liu Jianfang quit his teaching job at China’s Jilin University in 2019 to focus full-time on his semiconductor component maker GK Precision. He is now a billionaire after the company’s shares surged nearly 400% since its August listing.
The Kushner scion’s VC firm Thrive Capital nearly tripled its assets thanks to smart bets on OpenAI and SpaceX. Now he’s looking to spend some cash on the NBA’s Lakers.
For four generations, Rome’s Angelini family has built a $2.5 billion operation with drugs for depression and epilepsy in Europe. Now it’s bought its way into the U.S. market.
Chairman and CEO Wang Xingxing’s fortune surged nearly sevenfold to $16 billion as investors bet on China’s leading humanoid robot maker.
Despite billions in revenues, most influencers and their popular channels carry too much “key-person” risk for institutional investors. This UK firm has figured out how to turn viral videos into evergreen products.
The mogul, who launched a viral, 3-meter-tall transformable robot this year, has amassed a fortune of $2.4 billion derived from his equity stake.